about
Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?Effect of Preoperative Risk Group Stratification on Oncologic Outcomes of Patients with Adverse Pathologic Findings at Radical ProstatectomyThe urologist's view of male overactive bladder: discrepancy between reality and belief in practical setting.Pattern of failure in bladder cancer patients treated with radical cystectomy: rationale for adjuvant radiotherapy.Analgesic opioid dose is an important indicator of postoperative ileus following radical cystectomy with ileal conduit: experience in the robotic surgery era.Prognostic factors for urachal cancer: a bayesian model-averaging approach.Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged ≥70 years.Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer.The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.Repeat Targeted Prostate Biopsy under Guidance of Multiparametric MRI-Correlated Real-Time Contrast-Enhanced Ultrasound for Patients with Previous Negative Biopsy and Elevated Prostate-Specific Antigen: A Prospective Study.Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasiaPredicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP).Predictors of survival in prostate cancer patients with bone metastasis and extremely high prostate-specific antigen levelsPrognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate CancerComparison of computed tomography findings between renal oncocytomas and chromophobe renal cell carcinomas.Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.Inhibition of endoplasmic reticulum chaperone protein glucose-regulated protein 78 potentiates anti-angiogenic therapy in renal cell carcinoma through inactivation of the PERK/eIF2α pathway.Impact of caveolin-1 expression on the prognosis of transitional cell carcinoma of the upper urinary tract.Nomograms for prediction of disease recurrence in patients with primary Ta, T1 transitional cell carcinoma of the bladder.A multi-institutional study on histopathological characteristics of surgically treated renal tumors: the importance of tumor sizeA prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.Malfunction of da Vinci robotic system--disassembled surgeon's console hand piece: case report and review of the literature.Clinical significance of lymph node dissection in patients with muscle-invasive upper urinary tract transitional cell carcinoma treated with nephroureterectomy.Clinical experiences of incidental prostate cancer after transurethral resection of prostate (TURP) according to initial treatment: a study of a Korean high volume center.FOXC2 and CLIP4 : a potential biomarker for synchronous metastasis of ≤7-cm clear cell renal cell carcinomas.Charlson comorbidity index is an important prognostic factor for long-term survival outcomes in Korean men with prostate cancer after radical prostatectomy.Is high-dose leuprorelin acetate effective and safe in asian men with prostate cancer? An open-label, non-comparative, multi-center clinical trial.Indications for a second prostate biopsy in patients suspected with prostate cancer after an initial negative prostate biopsyLaparoendoscopic single-site (LESS) robot-assisted partial nephrectomy (RAPN) reduces postoperative wound pain without a rise in complication rates.The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.Early Application of Permanent Metallic Mesh Stent in Substitution for Temporary Polymeric Ureteral Stent Reduces Unnecessary Ureteral Procedures in Patients With Malignant Ureteral Obstruction.Does robot-assisted radical prostatectomy benefit prostate cancer patients with bone oligometastases?PI-RADS version 2: Preoperative role in the detection of normal-sized pelvic lymph node metastasis in prostate cancer.Prostate Cancer: PI-RADS Version 2 Helps Preoperatively Predict Clinically Significant Cancers.Targeting Integrin-Linked Kinase Suppresses Invasion and Metastasis through Downregulation of Epithelial-to-Mesenchymal Transition in Renal Cell Carcinoma.PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer.Inhibition of IGF-1 signaling by genistein: modulation of E-cadherin expression and downregulation of β-catenin signaling in hormone refractory PC-3 prostate cancer cells.Prognostic impact of preoperative neutrophil-to-lymphocyte ratio after radical prostatectomy in localized prostate cancer.Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study.
P50
Q28552864-B3107C8E-DCC9-4CDF-BC4F-CF45235CA045Q28554583-52297EEF-C912-4017-9850-E737BE408D9BQ33781988-E77D2D3E-4C72-45FF-823D-908D1979BE21Q33879717-E5DEFC02-53D1-4E19-9D15-70996A645FC7Q33941669-AF98D6F4-4D5D-44BC-B114-7EED3B82F8B4Q34196392-B499803E-41AD-43EF-9CBE-7916E953F2B0Q34294893-FE5C9E33-1444-45F9-BA5C-420327781F3CQ35040765-69684BA9-FAC0-4C7A-B5C6-D9BAA4BD8424Q35052701-91A44E01-AC44-4932-8644-F7AF335B7113Q35086041-E6D9E8D6-9123-4CC4-B934-6B6B60081992Q35665891-A5D7B8F2-7363-4CD3-895B-92B1A0827E5DQ35737705-7D890442-C453-4ADC-AE2B-25FB28549C2FQ35823355-AEF5C71D-1A6E-4740-82D6-9A95B66DE07FQ35827731-41187CB6-A3F8-4248-8312-A74002B0511FQ35971011-0D4EF589-3969-4B76-B965-8EB05B344CFEQ36177109-228FE0C9-AAA6-427F-BA4D-2B8FFA9F8C74Q36378883-99A92FF1-10D8-4FE8-B187-03B40533337BQ36544227-15DE8199-6311-47B8-899B-F095AC299493Q36854227-F15F2CC1-7916-49F7-BE67-0328AD6BCE70Q36854613-F2F49E43-BD4F-4740-A2B6-BA0F7ABA67B9Q37040918-5E690DDA-FA03-4504-ABD3-DB618F8A773FQ37065684-E4FF497C-F34F-42B6-AD0E-2AA82BFDD67CQ37126919-77D5EECF-CA1B-4B77-AD81-B6BBDA614FC1Q37284763-3525834D-A9F2-4393-AC99-0EA62DFEEB41Q37418799-199E370B-4FF3-46CF-A8DC-7D7CD4A0C013Q37588300-E69EBAB6-259D-4C90-9182-624E0E10B543Q37606713-ABDF8EEE-226F-429C-BA9F-70B61EE25B8CQ37606746-6B94FF6C-5EBF-4EDF-A508-661003DAB326Q37710933-D94D9352-0097-4128-8F20-E8B3C42369B5Q38222634-F21A204D-B808-4582-A5AF-99FD5AA6D657Q38500334-6C353169-87BC-47DA-A097-125189C52BDFQ38542759-A851400D-72E5-46C8-A327-8BFF09CA5DC7Q38611785-19460B15-DFC0-495E-9B47-D31298097FDFQ38718769-50807655-A654-407C-A595-210D016F5914Q38719607-314DBD2D-04E2-4DA4-8C72-6A05C07706D1Q38912381-75454841-B012-4025-B273-CE5BB1115FE2Q39106378-9B6C9E7A-6145-4DAB-936A-1A0559F3644CQ39440714-5A0C9330-B7AB-4549-BF02-03D7F7CAC8CAQ39651226-4B40B330-943D-4F6C-9701-4AE3C3D4462DQ39744709-C39EE2BC-D37F-46F3-9157-C3941AE1AEDB
P50
description
researcher ORCID ID = 0000-0001-9869-065X
@en
name
Sung Joon Hong
@ast
Sung Joon Hong
@en
Sung Joon Hong
@es
Sung Joon Hong
@nl
type
label
Sung Joon Hong
@ast
Sung Joon Hong
@en
Sung Joon Hong
@es
Sung Joon Hong
@nl
prefLabel
Sung Joon Hong
@ast
Sung Joon Hong
@en
Sung Joon Hong
@es
Sung Joon Hong
@nl
P31
P496
0000-0001-9869-065X